GSK’s Jemperli Receives Priority FDA Review for Rectal Cancer Treatment

FDA Fast-Tracking Jemperli for Rectal Cancer

GSK’s cancer drug Jemperli is under priority review by the U.S. Food and Drug Administration (FDA). This follows a pivotal study showing significant benefits for rectal cancer patients. A notable portion showed no tumor signs for a year after the trial. This development could redefine treatment approaches for rectal cancer, lowering the dependence on invasive methods like chemotherapy, radiation, and surgery.

The FDA has set a decision deadline for February 2027, but accelerated consideration under the National Priority Voucher program could bring a quicker decision. The application is also under review through Project Orbis, which facilitates international approval coordination.

Results from the AZUR-1 Trial

The FDA’s review hinges on data from the AZUR-1 trial. This phase II trial assessed Jemperli for untreated stage II and III dMMR/MSI-H locally advanced rectal cancer.

The trial met its primary endpoint, indicating clinical complete responses for at least a year. Hesham Abdullah, GSK’s senior vice president in oncology R&D, noted substantial improvements compared to historical standards. The study involved 154 patients receiving nine Jemperli cycles over six months, with interim safety results aligning with known drug profiles.

Interim data confirmed Jemperli’s safety and tolerability, consistent with its established profile across tumor types.

Potential Shift from Conventional Treatment

Historically, dMMR/MSI-H rectal cancer involved chemotherapy, radiation, and surgery. Despite curative intents, these treatments lead to lasting adverse effects.

Abdullah described potential long-term issues patients face, like permanent dependence on a colostomy bag and complications in bowel, urinary, and sexual functions. Fertility loss during treatment is another concern.

If Jemperli is approved as a first-line option, selected patients could sidestep these invasive procedures and their consequences.

Immunotherapy’s Role in Cancer Treatment

The AZUR-1 findings build on prior research showing PD-1 blockade effectiveness without chemotherapy. dMMR/MSI-H tumors, carrying numerous genetic changes, are more visible to the immune system, making them responsive to immunotherapy.

Abdullah explained the mechanism: Jemperli, an anti-PD-1 therapy, aids immune cells in attacking cancer by removing inhibitory ‘brakes’ on them. Biomarker testing for dMMR/MSI-H is crucial, although it doesn’t guarantee universal patient response.

Next Steps and Regulatory Process

The FDA’s review deadline is February 2027, but priority considerations might quicken the process. Project Orbis participation allows international synchronization in evaluations.

Abdullah highlighted priority features such as Fast Track and Breakthrough Therapy designations, along with Orbis participation, emphasizing urgency due to limited patient options.

If approved, Jemperli would inaugurate an immunotherapy-first strategy, shifting treatment pathways. Biomarker testing would gain prominence earlier in diagnosis.

GSK’s Expanding Oncology Portfolio

GSK’s oncology program has grown in recent years, with Jemperli central to its immuno-oncology strategy. The company’s stock has shown a 9.7% increase year-to-date, signifying investor optimism.

Abdullah termed the AZUR-1 milestone vital for scientific innovation. GSK is progressing Phase 3 trials in gastrointestinal cancers, targeting gaps in care. Future data presentations are planned.

Contact Newsweek editors Samantha Beech and Dave Siminoff for more information on this story.